Thymalin is not a single molecule. It is a polypeptide complex extracted from calf thymus tissue, developed in 1981 by Vyacheslav Morozov and Vladimir Khavinson in Leningrad. The preparation contains a mix of short peptides rather than one defined compound, which is the first thing to get straight about it.
That matters because Thymalin is often confused with thymulin. They are different things. Thymulin (also called serum thymic factor or nonathymulin, CAS 63958-90-7) is a specific endogenous nonapeptide, sequence Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, with a molecular weight around 859 Da, and its T-cell activity depends on zinc. Thymalin is a heterogeneous extract of larger molecular weight. The chemical aliases sometimes attached to "Thymalin" listings (the nonapeptide sequence, PubChem's nonathymulin entry) actually describe thymulin. Read product pages with that in mind.
What it is and how it is described to work
Thymalin sits in the family of thymic peptide preparations meant to support flagging immune function, alongside thymosin alpha-1 and others. Its proposed mechanism, as described by Khavinson's group, comes from short peptides in the mixture (they name KE, EW, and EDP) that they say bind double-stranded DNA and histone proteins and influence gene expression, immune-protein synthesis, and T-cell differentiation. Treat that as the originators' proposed mechanism rather than independently established fact.
State of the evidence
There is a real clinical literature here, which sets Thymalin apart from many obscure research peptides. The honest catch is that almost all of it comes from one source: Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, much of it published in Russian-language journals. Independent Western randomized controlled trials are missing.
The most cited paper is a long-term observational study. Khavinson and Morozov followed 266 elderly people over six to eight years, giving bioregulators (Thymalin, the pineal peptide epithalamin, or both) during the first two to three years. They reported mortality reductions versus controls: roughly a 2-fold decrease with Thymalin alone, and larger reductions with combined and repeated treatment (Khavinson & Morozov, *Neuro Endocrinol Lett* 2003). It was not a blinded randomized trial, and the effect sizes are large enough to warrant caution.
More recently, the same lineage of researchers studied Thymalin in severe COVID-19 in older patients. Patients given Thymalin on top of standard therapy were reported to recover faster from lymphopenia and to normalize inflammatory markers more quickly, with shifts in T-cell surface markers (*Advances in Gerontology* 2021). This was a small study from the group that develops the drug, so it is a signal, not proof.
Regulatory and quality notes
Thymalin has been registered for medical use by the Russian Ministry of Health since the early 1980s and is manufactured there (by Samson-Med). It is not approved by the FDA or EMA. Outside Russia and a few neighboring countries it is sold as a "research only" material, not a medicine, and is not approved for human consumption. Nothing here is medical or dosing advice.
For anyone evaluating a product labeled "Thymalin," the identity problem is the practical issue. Because it is a complex extract and not a single molecule, a certificate of analysis cannot show a clean single-compound purity the way it can for a defined peptide. Buyers should look at what the COA actually claims, whether the vendor distinguishes Thymalin from thymulin, and what independent identity or composition testing exists. peptideone aggregates third-party COAs and vendor ratings where they are available; for a heterogeneous extract like this, the gap between label and contents is exactly the thing worth checking.